EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom

Monica Hernandez Alava, Allan Wailoo, Sabine Grimm, Stephen Pudney, Manuel Gomes, Zia Sadique, David Meads, John O'Dwyer, Garry Barton, Lisa Irvine

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)49-56
Number of pages8
JournalValue in Health
Volume21
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • cost effectiveness
  • EQ-5D
  • health utility
  • RANDOMIZED CONTROLLED-TRIAL
  • EARLY RHEUMATOID-ARTHRITIS
  • VALUE SET
  • HEALTH STATES
  • DISEASE
  • GLUCOCORTICOIDS
  • DRUGS

Cite this

Alava, M. H., Wailoo, A., Grimm, S., Pudney, S., Gomes, M., Sadique, Z., Meads, D., O'Dwyer, J., Barton, G., & Irvine, L. (2018). EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. Value in Health, 21(1), 49-56. https://doi.org/10.1016/j.jval.2017.09.004